SLC5A2 and type 1 diabetes mellitus: Most studies showing the renoprotective effects of SGLT-2 inhibitors included people with type 2 diabetes [23,24], while a recent meta-analysis by Karakasis et al. showed that using SGLT-2 inhibitors as an additional treatment in individuals with type 1 diabetes led to a notable decrease in albuminuria, whereas their usage had a neutral impact on creatinine clearance [25].